RCS - Physiomics PLC - Contract Award

PhysiomicsAnnouncement

19/02/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240219:nRSS5153Da&default-theme=true

RNS Number : 5153D  Physiomics PLC  19 February 2024

19 February 2024

 

Physiomics plc

("Physiomics" or the "Company")

 

Contract Award

 

Physiomics plc (AIM: PYC), a leading mathematical modelling and data science
company supporting the development of new therapeutics and personalised
medicine solutions, is pleased to announce that it has been chosen by The
University of Sheffield (the "University") to support a grant funded project
focused on an insect (Fruit fly) model of cancer treatment.  The value of
this work to Physiomics will be £45k and will commence in the second half of
this calendar year.  The work is in support of one of seven cancer-focused
projects recently announced by the University
(https://www.sheffield.ac.uk/news/future-cancer-research-yorkshire-receives-ps89-million-funding-boost
(https://www.sheffield.ac.uk/news/future-cancer-research-yorkshire-receives-ps89-million-funding-boost)
), all of which will be funded by Yorkshire Cancer Research.

 

This work follows on from a pilot project with the University, funded by the
UK Research and Innovation (UKRI) Higher Education Innovation Funding (HEIF)
scheme (announced 31 May 2023), and Physiomics will once again be working with
principal investigator Dr Kyra Campbell, who has led a significant programme
of research in this field since December 2021. The project is focused on the
development of an insect model of cancer that could be used to screen new
drugs prior to pre-clinical testing in more traditional models of cancer and
has a particular focus on the prediction of metastasis.  This new approach
could provide important insights into the development of novel cancer
therapies as well as potentially reduce the number of pre-clinical animals
involved in the drug development process.  Physiomics' role will be to create
mathematical models based on experimental data generated by Dr Campbell and
her team and explore the relationship between the effect of drugs in these
models, established models and humans.  Physiomics will also provide advice
and guidance on the possible commercialisation of the technology.

 

Dr Peter Sargent, CEO of Physiomics, commented:

"We are delighted to have been selected once again by The University of
Sheffield to support a highly innovative research program with our analytical
and modelling capabilities.  We look forward to working with Dr Campbell and
her colleagues and believe that both our analytical capabilities, as well as
our contacts and experience within the pharmaceutical industry, could add real
value to the initiative."

 

 

 

Enquiries:

 

Physiomics plc

Dr Peter Sargent, CEO

+44 (0)1235 841575

 

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

 

 

Notes to Editor

 

About Physiomics

 

Physiomics plc combines cutting edge PKPD and QSP modelling and data science
techniques, along with deep biology expertise, to help biotech and pharma
companies streamline their drug development journeys.

 

Our approach is to derive insight from all relevant data in order to de-risk
decision making and optimise design research across discovery, pre-clinical
and clinical studies.

 

Through use of bespoke models and our proprietary Virtual Tumour technology,
the Physiomics team has informed the development of over 100 commercial
projects, over 50 targets and 75 drugs. Clients include Merck KGaA, Astellas,
Bicycle Therapeutics, Numab Therapeutics & CRUK.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAGPUGWPUPCGRQ